(NASDAQ: OCUP) Ocuphire Pharma's forecast annual revenue growth rate of 46.92% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Ocuphire Pharma's revenue in 2024 is $19,049,000.On average, 1 Wall Street analysts forecast OCUP's revenue for 2024 to be $374,930,021, with the lowest OCUP revenue forecast at $374,930,021, and the highest OCUP revenue forecast at $374,930,021. On average, 1 Wall Street analysts forecast OCUP's revenue for 2025 to be $759,785,389, with the lowest OCUP revenue forecast at $759,785,389, and the highest OCUP revenue forecast at $759,785,389.
In 2026, OCUP is forecast to generate $1,569,941,920 in revenue, with the lowest revenue forecast at $1,569,941,920 and the highest revenue forecast at $1,569,941,920.